Annals of Oncology 12:457-462, 2001
© 2001 European Society for Medical Oncology
research-article |
Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin's lymphoma*
1University of Southern California Schools of Medicine and Pathology Los Angeles, California
2Northwest Kaiser Permanente Portland, Oregon
3North Shore University Hospital Manhacset, New York
4Scripps Memorial Hospital La Jolla, California
5School of Medicine, Denver General Hospital Denver, Colorado
6Northwestern University Medical School Chicago, Illinois
7Breslin Cancer Center Lansing, Michigan
8Pacific Coast Hematology/Oncology Medical Group Fountain Valley, California
9Michigan Cancer Center East Lansing. Michigan
10Nexstar Pharmaceuticals Boulder, Colorado, USA
Correspondence to: A Tulpule, MD Norns Cancer Hospital and Research Institute 1441 Eastlake Avenue NOR 3461 MC 9172 Los Angeles, CA 90089 USA E-mail Tulpule{at}hsc.use.edu
Purpose To assess the efficacy and toxicity of liposomal dauno-rubicin administered as a two-hour intravenous infusion to patients with relapsed or refractory non-Hodgkin's lymphoma (NHL)
Patients and methods Eligible patients had relapsed or refractory NHL with measurable or evaluable disease, and low grade, select intermediate grade, or mantle cell pathologic types. Prior exposure to an anthracycline or anthracenedione was allowed. Liposomal daunorubicin at a dose of 100 mg/m2 was given intravenously over a minimum of 120 minutes every 3 weeks, as a single agent
Results Thirty-three patients were accrued twenty-three (70%) had low-grade histologies, six (18%) had intermediate-grade histologies (follicular large-cell and diffuse small cleaved), and four (12%) patients had mantle-cell lymphoma Eighteen (55%) had received two or more prior regimens, fourteen (42%) received a prior anthracycline A median of six cycles of liposomal daunorubicin were administered (range 1–15) of 31 patients evaluable for response, 2 complete and 10 partial remissions were documented for a major response rate of 39% (95% confidence interval (Cl)1 22%–58%). The median duration of response was 19 5 months (range 4.3–41.1+) Six responders (50%) had received a prior anthracycline, one responder had mantle-cell histology The major toxicities were grade 3 or 4 neutropenia in 26 patients (79%), mild to moderate nausea in 22 (67%), and fatigue in 16 (48%)
Conclusions Liposomal daunorubicin at 100 mg/m2 every three weeks has activity in patients with relapsed or refractory NHL, including patients with prior exposure to an anthracy-cline Further studies of liposomal daunorubicin in combination with other agents are warranted
anthracyclines, liposomal daunorubicin, low-grade, lymphoma, NHL